Amicus Therapeutics (NASDAQ:FOLD) has been under a strong bear grip, hence the stock is down -2.4% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 3.21% in the past 1 week. The stock has risen by 4.53% in the past week indicating that the buyers are active at lower levels, but the stock is down -0.83% in the past 4 weeks.
The company shares have dropped -59.18% from its 1 Year high price. On Aug 5, 2015, the shares registered one year high at $18.83 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $6.29 and the 200 Day Moving Average price is recorded at $7.12.
The stock has recorded a 20-day Moving Average of 3.76% and the 50-Day Moving Average is 7.78%.
Amicus Therapeutics (NASDAQ:FOLD): On Fridays trading session , Opening price of the stock was $6.25 with an intraday high of $6.34. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $5.87. However, the stock managed to close at $6, a loss of 2.76% for the day. On the previous day, the stock had closed at $6.17. The total traded volume of the day was 2,368,848 shares.
In an insider trading activity, Rosenberg Ellen, officer (General Counsel & Corp. Secy) of Amicus Therapeutics Inc, executed a transaction worth $115,050 on June 2, 2016. A total of 15,000 shares were purchased at an average price of $7.67. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.